Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

RPR forms worldwide research collaboration to study Taxotere-based combinations

March 6, 1997

MGH to evaluate Cheung breast cancer treatment system in animals

March 6, 1997

Selective, nonpeptide inhibitor of Ras farnesylation discovered by Schering-Plough

March 6, 1997

MAb for metastasis or ischemia reported by BU

March 6, 1997

TK inhibitors from Novartis

March 6, 1997

Oral mucositis treatment proceeds to phase II

March 5, 1997

Update on Sparta's asulacrine

March 5, 1997

Caelyx available in additional countries

March 5, 1997

Orally active inhibitor of Ras farnesylation reported by Schering-Plough

March 5, 1997

Steroidal antitumor agents described by Taisho

March 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...